Investigating how a protein called LRG1 affects colorectal cancer spread to the liver
Role of LRG1 in colorectal cancer tumorigenesis
This study is looking at a protein called LRG1 to see how it affects the growth of metastatic colorectal cancer in the liver, with the hope of finding new treatment options for patients dealing with this type of cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11021076 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein known as leucine rich alpha-2-glycoprotein 1 (LRG1) in the development of metastatic colorectal cancer (mCRC), particularly how it influences cancer growth in the liver. The study aims to explore how liver endothelial cells secrete LRG1 and how this protein activates a receptor called HER3, which is linked to cancer progression. By examining the mechanisms of LRG1 and its interaction with HER3, researchers hope to uncover new insights that could lead to innovative treatments for patients with mCRC. The research will involve laboratory experiments and animal models to validate the findings and assess the potential for therapeutic interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic colorectal cancer, particularly those with liver metastases.
Not a fit: Patients with localized colorectal cancer or those without liver involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that inhibit LRG1, potentially improving outcomes for patients with metastatic colorectal cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Wang, Rui — Case Western Reserve University
- Study coordinator: Wang, Rui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.